U.S. politician makes super suspicious $500k healthcare stock trade

U.S. Representative Kevin Hern has drawn renewed attention following a recent transaction involving healthcare insurance giant UnitedHealth Group (NYSE: UNH).

Disclosure filings show that Hern’s Congress trade involved selling his entire UnitedHealth stake on December 23, 2025, in a transaction valued between $250,001 and $500,000. 

The sale, reported on January 22, 2026, was marked as a sell to close, confirming a full exit. At the time, UnitedHealth shares were trading near recent lows after a volatile year for the insurer.

The timing has drawn interest given Hern’s role on the House Ways and Means Subcommittee on Health, which oversees Medicare, Medicaid, and other policies that directly impact insurers like UnitedHealth. 

The company faced sustained pressure in 2025 from rising medical costs, Medicare Advantage margin compression, regulatory scrutiny, and management upheaval, driving sharp swings in its share price.

UNH shares rebound 

Since Hern’s Congress trade, UnitedHealth shares have climbed more than 9%, outperforming the broader market over the same period. That rebound has fueled questions over whether the sale reflected poor market timing, a loss-driven exit, or expectations tied to policy developments that ultimately failed to materialize.

Hern’s trading history in UnitedHealth further complicates the narrative. In this line, between October 7, 2021, and July 15, 2024, he bought UnitedHealth shares on 12 separate occasions, steadily building the position while the company was widely viewed as a defensive healthcare leader. 

He held the entire stake through UnitedHealth’s 2025 downturn and exited only after the stock had already suffered sharp declines. Based on disclosed transaction ranges and price history, the position was underwater across all 12 purchases at the time of sale.

The episode has also highlighted the broader debate around trimming strategies and dollar-cost averaging. Although Hern accumulated shares over several years, the absence of partial profit-taking during stronger periods left him fully exposed to the 2025 selloff. Selling the entire stake near the end of a difficult year, rather than gradually reducing exposure, contrasts with common portfolio risk-management practices.

UnitedHealth stock woes 

UnitedHealth Group’s stock plunged in 2025 as a series of operational and regulatory setbacks weighed heavily on investor confidence. The insurer was hit by sharply rising medical costs, particularly within its Medicare Advantage business, where higher patient utilization drove margin compression and forced multiple earnings forecast cuts.

Pressure intensified when UnitedHealth withdrew its full-year guidance, signaling reduced visibility into costs and profitability. The situation was further unsettled by abrupt management changes, raising concerns about leadership stability during a critical period.

Adding to the turmoil, increased regulatory scrutiny and reports of government investigations into Medicare billing practices introduced legal and reputational risks. However, the stock has since staged a recovery, supported by improving sentiment and growing insider confidence in the company.

Featured image via Shutterstock